Cocrystal Pharma (COCP) announces it has received a Small Business Innovation Research, SBIR, Phase I award from the National Institutes of Health, NIH, National Institute of Allergy and Infectious Diseases, NIAID. This approximately $500,000 award will support the Company’s development of a novel, oral, broad-spectrum antiviral candidate for the treatment of influenza A and B infections. Cocrystal plans to utilize these funds to characterize lead candidate molecules that inhibit the target of the essential function of the influenza polymerase complex.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCP:
- Cocrystal Pharma files to sell 5.74M shares of common stock for holders
- Cocrystal Pharma Raises $4.75M in Direct Offering
- Cocrystal Pharma Announces Stock Offering and Warrant Placement
- Cocrystal Pharma Advances CDI-988 to Phase 1b Study
- Cocrystal Pharma announces up to $13M registered direct offering